Trial Profile
An Open Label, Single-Dosing, and Parallel Study in Healthy Elderly and Young Male Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2020
Price :
$35
*
At a glance
- Drugs Fimasartan (Primary)
- Indications Essential hypertension; Hypertension
- Focus Pharmacokinetics
- Sponsors Boryung Pharmaceutical
- 07 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Nov 2009 Actual initiation date (Aug 2009) added as reported by ClinicalTrials.gov.
- 15 Jul 2009 New trial record